BRINP2-Derived Peptide Composition for Appetite and Weight Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological and lifestyle interventions for weight management have limited efficacy due to counterregulatory mechanisms, and there is a lack of understanding about endogenous peptides that control feeding behavior and obesity development.
Innovation Solution
Development of BRINP2-related peptide (BRP) compositions that reduce food intake and obesity by administering a therapeutically effective amount of the peptide, which can be modified for increased biological half-life and specificity, alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If modified GLP-1 peptide analogs (liraglutide, semaglutide) are used for weight loss, then body weight reduction is improved, but the complexity of peptide modification and formulation increases
Solution Approach 1:
The patent extracts and utilizes the active peptide sequence (amino acids 116-127 of BRINP2) from its parent protein through proteolytic cleavage. This extraction approach identifies the minimal functional unit responsible for food intake reduction, avoiding the need for extensive peptide modifications while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs proteolytic cleavage to change the molecular parameters of the parent BRINP2 protein, generating a smaller, more stable active peptide fragment. This parameter change (from full-length protein to cleaved peptide) simplifies the therapeutic agent while preserving the weight loss effect.
2Measurement precision
If extensive proteomics efforts are used to detect peptide hormones, then detection capability is improved, but the difficulty of detecting low-abundance peptides remains
Solution Approach 1:
The patent performs preliminary proteolytic cleavage of the parent BRINP2 protein to generate the active peptide fragment before detection or therapeutic use. This preliminary action concentrates the active species and makes it detectable and可利用able, overcoming the low-abundance detection problem.
3Adaptability or versatility
If peptide hormones are synthesized as larger precursors, then functional versatility is improved, but the difficulty of detecting dynamic regulation increases
Solution Approach 1:
The patent extracts the dynamically regulated active peptide (amino acids 116-127) from its precursor through proteolytic cleavage. This extraction enables direct detection and measurement of the active form, revealing the dynamic regulation that was previously obscured within the larger precursor protein.
4Ease of operation
If behavioral and lifestyle changes are used for weight loss, then intervention simplicity is improved, but weight loss efficacy is worsened
Solution Approach 1:
The patent introduces BRP as a pharmacological intermediary that mediates between simple administration and complex physiological effects. The peptide acts as a mediator that enhances satiety and reduces food intake, providing weight loss efficacy that supplements behavioral and lifestyle interventions without requiring complex procedures.
Data Source
AI summary
Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. It is shown herein that a peptide that is proteolytically cleaved from the parent protein BRINP2 is effective in reducing food intake and obesity in a mammal. The peptide is referred to herein as BRNP2 expression in as BRINP2-related peptide (BRP).